Givaudan is revamping product development across its beauty and fragrance divisions as weight loss treatments reshape consumer budgets, tracked by 15 generic semaglutide brands entering India since patent expirations began. The ingredient supplier found adult adoption of GLP-1 therapies in the US climbed from 3 per cent in 2024 to 11 per cent in 2026, triggering direct reallocation of discretionary spending.
Data compiled by the manufacturer from a NielsenIQ Homescan panel revealed American households using the medications increased spending on fine fragrances by 97 per cent while cutting grocery budgets. In Brazil, 47 per cent of buyers reported trimming other expenses specifically to finance treatment doses, signaling a widespread behavioral reallocation away from food toward personal grooming, sports, and travel.
India Generics Drive Rapid Market Expansion
Price reductions and the loss of patent exclusivity in markets such as India have dismantled entry barriers for metabolic therapies. The introduction of 15 domestic brands following patent expiries expanded regional supply rapidly, lowering therapy costs and broadening usage beyond narrow clinical segments.
Lower retail prices combined with the development of oral alternatives to subcutaneous injections are speeding up adoption across emerging economies. For personal care brands operating in Asia, this shift alters the customer base faster than anticipated. Product developers must adjust formulas for consumers managing the physiological consequences of rapid weight reduction.
Formulations Adapt to Side Effects
Patients experience specific physiological issues that prompt new topical requirements, notably loss of facial volume, loose skin, barrier dryness, temporary hair thinning, and bad breath. Consumers navigating these side effects prioritize demonstrable performance over brand prestige, checking active concentrations and clinical validation closely.
Buyers demand formulas that combine medical-grade efficacy with sensory textures. Frédéric Merlin, manager of the Givaudan Digital Factory in Paris, stated: “Faced with these very real concerns, consumers are becoming more demanding: they seek out the right actives, compare concentrations, and check the evidence behind efficacy claims. But they are unwilling to choose between performance and pleasure. They expect visible results, sensorial textures, and an enjoyable experience. Whereas a brand’s reputation may once have been enough to win them over, it is now the efficacy promise, backed by evidence, that makes the difference.”
Scent Profiles Reflect Appetite Changes
Social listening data gathered by Givaudan identified two dominant fragrance profiles among treatment users: gourmand compositions and crisp, fresh notes. Appetite suppression does not eliminate interest in rich food-inspired aromas, although nausea risks create sharp aversions to heavy notes, requiring finer calibration by perfumers.
Energy dips and sleep disruptions linked to these therapies have opened room for functional scents. Givaudan is deploying its patented MoodScentz and DreamScentz platforms, pitching neuro-olfactive formulations that stimulate alertness in the morning or support disrupted sleep cycles at night.
Digital Factory Tests Commercial Concepts
The company developed an exhibition format called The New Desire at its Paris Digital Factory, built around an artificial intelligence persona named Nathalie to model shifting habits. Brand teams examine over 120 global product rollouts and generate concept packaging tested against simulated consumer feedback.
Corporate clients have booked repeat sessions at the facility, prompting an operational extension of the program. Fast-moving consumer goods suppliers across the Asia-Pacific region now face parallel realignments on retail shelves: packaged food volumes face headwinds, while functional personal care and premium fragrances capture liberated wallet share.
Givaudan plans to publish its next wave of field research on GLP-1 olfactory preferences before the end of 2026.
